Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis
| Autor: | Erika J. Sims, Graeme P. Currie, Daniel K. C. Lee, Brian J. Lipworth, F.M. Robb, Lesley C. McFarlane |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Pharmacology
Creatinine medicine.medical_specialty Triamcinolone acetonide medicine.drug_class business.industry Washout Mometasone furoate Placebo Gastroenterology chemistry.chemical_compound chemistry Pharmacokinetics Internal medicine Anesthesia medicine Corticosteroid Pharmacology (medical) business Glucocorticoid medicine.drug |
| Zdroj: | British Journal of Clinical Pharmacology. 55:310-313 |
| ISSN: | 0306-5251 |
| DOI: | 10.1046/j.1365-2125.2003.01729.x |
| Popis: | Aims To evaluate the systemic bioactivity of triamcinolone acetonide (TA) 220 µg or mometasone furoate (MF) 200 µg over 3 weeks in perennial allergic rhinitis. Methods Twenty-seven patients received TA 220 µg or MF 200 µg once daily for 3 weeks with a 2 week placebo washout period prior to each randomized treatment. Measurements were made at baseline after each washout and after each randomized treatment, comprising overnight 10-h urinary cortisol corrected for creatinine (OUCC), 08.00 h plasma cortisol and 08.00 h serum osteocalcin. Results There were no significant differences between baseline values prior to TA or MF, and for any outcome measures comparing randomized treatments to respective baseline values or comparing TA with MF. For OUCC compared with baseline, the geometric mean fold suppression (95% CI) was 1.02 (0.78, 1.33) for TA (2% decrease), 1.07 (0.80, 1.42) for MF (7% decrease), and 1.05 (0.79, 1.39) for TA vs MF (5% decrease). Conclusions Standard doses of TA or MF over 3 weeks showed no differences in systemic bioactivity markers compared with respective baseline values after placebo washout, and there were no differences between TA vs MF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text